Efficacy of toxin-A botulinum for treating intractable bladder hypractivity in children affected by neuropathic bladder secondary to myelomeningocele: An alternative to enterocistoplasty;La tossina A-botulinica in bambini con vescica neurogena iperattiva secondaria a mielomeningocele refrattaria agli urofarmaci: Una alternativa all'enterocistoplastica

Minerva Pediatrica

Volumn 57, Issue 1, 2005, Pages 35-40

  Marte, A ^a   Vessella, A ^a   Cautiero, P ^a   Romano, M ^a   Borrelli, M ^a   Noviello, C ^a   Del Gado, R ^a   Parmeggiani, P ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Bladder diseases; Botulinum toxin type A; Myelomeningocele

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ADOLESCENT; ARTICLE; BLADDER DYSFUNCTION; BLADDER RECONSTRUCTION; CATHETERIZATION; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTOGRAPHY; DETRUSOR MUSCLE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; HYPERACTIVITY; MALE; MENINGOMYELOCELE; MUSCLE CONTRACTION; NEUROPATHY; RANK SUM TEST; ULTRASOUND; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; URODYNAMICS; VESICOURETERAL REFLUX; COMPARATIVE STUDY; EVALUATION; INTRAMUSCULAR DRUG ADMINISTRATION; NEUROGENIC BLADDER; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RADIOGRAPHY; SCINTISCANNING; STATISTICAL ANALYSIS; TIME; TREATMENT OUTCOME;

ADOLESCENT; BOTULINUM TOXIN TYPE A; CHILD; CHILD, PRESCHOOL; DATA INTERPRETATION, STATISTICAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MENINGOMYELOCELE; NEUROMUSCULAR AGENTS; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER, NEUROGENIC; URINARY INCONTINENCE; URODYNAMICS; VESICO-URETERAL REFLUX;

EID: 18944375029     PISSN: 00264946     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Madersbacher H. Neurogenic bladder dysfunction in patients with myelomeningocele. Curr Opin Urol 2002;12:469-72.
2. Del Popolo G. La tossina botulinica in neurourologia. Somipar 2001;285-9.
3. Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-7.
4. Schulte-Baukloh H, Michael T, Sturzebecher B, Knispel HH. Botulinum-a toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur Urol 2003;44:139-43.
5. Mc Guire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value urodynamic testing in myelodysplastic patients. J Urol 1981;126:205-8.
6. Houle AM, Gilmour RF, Churchill BM, Gaumond M, Bissonnette B. What volume can a child normally store in the bladder at a safe pressure? J Urol 1993;149:561-4.
7. Phelan MW, Franks M, Somogyi GT, Yokohama T, Fraser MO, Laavelle JP et al. Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 2001;165:1107-10.
8. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:100-3.
9. Dolly O. Synaptic transmission: inhibition of neurotransmitter release by botulinum toxins. Headache 2003;43:16-24.
10. Denys P, Even-Schneider A, Thiry Escudie I, Ben Small D, Ayoub N, Chartier-Kastler E. Efficacy of botulinum toxin A for the treatment of detrusor hyperreflexia. Ann Readapt Med Phys 2003;46:326-8.
11. Leippold T, Reitz A, Schurch B. Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 2003;44:165-74.
12. Klein AW. Complications and adverse reactions with the use of botulinum toxin. Dis Mon 2002;48:336-56.
13. Dressler D, Munchau A, Bhatia KP, Quinn NP, Bigalke H. Antibody-induced botulinum toxin therapy failure: can it be overcome by increased botulinum toxin doses? Eur Neurol 2002;47:118-21.